Skip to main content
Premium Trial:

Request an Annual Quote

Medicare Jurisdictions Add Coverage for CareDx's AlloMap Test

NEW YORK (GenomeWeb) – CareDx today announced that two Medicare Administrative Carrier jurisdictions have issued positive decisions on covering its AlloMap molecular diagnostic surveillance test for heart transplant patients, extending coverage to Medicare patients in 11 additional states.

Four of the 12 MAC jurisdictions now cover the test. The newly affected states are Ohio, Kentucky, Oregon, Washington, Arizona, Utah, Idaho, Montana, North Dakota, South Dakota, and Wyoming.

CareDx said in a statement that one result of the expanded coverage is that patients in the affected states can now have their blood drawn onsite at the clinic of their choice and not at a secondary location, as was previously required.

AlloMap is a non-invasive test to indicate the risk of heart transplant rejection. The multi-gene molecular expression test has been covered by Medicare since 2006 and was cleared by the US Food and Drug Administration in 2008.